Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Corrigendum: Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics.

Vaara M.

Front Microbiol. 2019 Oct 1;10:2275. doi: 10.3389/fmicb.2019.02275. eCollection 2019.

2.

Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics.

Vaara M.

Front Microbiol. 2019 Jul 25;10:1689. doi: 10.3389/fmicb.2019.01689. eCollection 2019. Erratum in: Front Microbiol. 2019 Oct 01;10:2275.

3.

Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.

Vaara M.

Molecules. 2019 Jan 11;24(2). pii: E249. doi: 10.3390/molecules24020249. Review.

4.

The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.

Tyrrell JM, Aboklaish AF, Walsh TR, Vaara T, Vaara M.

Peptides. 2019 Feb;112:149-153. doi: 10.1016/j.peptides.2018.12.006. Epub 2018 Dec 23.

PMID:
30586602
5.

Human kidney on a chip assessment of polymyxin antibiotic nephrotoxicity.

Weber EJ, Lidberg KA, Wang L, Bammler TK, MacDonald JW, Li MJ, Redhair M, Atkins WM, Tran C, Hines KM, Herron J, Xu L, Monteiro MB, Ramm S, Vaidya V, Vaara M, Vaara T, Himmelfarb J, Kelly EJ.

JCI Insight. 2018 Dec 20;3(24). pii: 123673. doi: 10.1172/jci.insight.123673.

6.

Non-tuberculous Mycobacteria can Cause Disseminated Mycobacteriosis in Cats.

Pekkarinen H, Airas N, Savolainen LE, Rantala M, Kilpinen S, Miuku O, Speeti M, Karkamo V, Malkamäki S, Vaara M, Sukura A, Syrjä P.

J Comp Pathol. 2018 Apr;160:1-9. doi: 10.1016/j.jcpa.2018.02.002. Epub 2018 Mar 27.

PMID:
29729715
7.

Power of lower extremities is most important determinant of agility among physically inactive or active adult people.

Manderoos S, Vaara M, Karppi SL, Aunola S, Puukka P, Surakka J, Mälkiä E.

Physiother Res Int. 2018 Jul;23(3):e1716. doi: 10.1002/pri.1716. Epub 2018 Apr 26.

PMID:
29698582
8.

New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.

Vaara M.

Med Res Rev. 2018 Sep;38(5):1661-1673. doi: 10.1002/med.21494. Epub 2018 Feb 27. Review.

PMID:
29485690
9.

Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis.

Vaara M, Vaara T, Vingsbo Lundberg C.

J Antimicrob Chemother. 2018 Feb 1;73(2):452-455. doi: 10.1093/jac/dkx394.

PMID:
29149329
10.

Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741.

Corbett D, Wise A, Langley T, Skinner K, Trimby E, Birchall S, Dorali A, Sandiford S, Williams J, Warn P, Vaara M, Lister T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00200-17. doi: 10.1128/AAC.00200-17. Print 2017 Aug.

11.

Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity.

Vaara M, Vaara T, Tyrrell JM.

Peptides. 2017 May;91:8-12. doi: 10.1016/j.peptides.2017.03.002. Epub 2017 Mar 11.

PMID:
28300674
12.

Human DNA polymerase α interacts with mismatch repair proteins MSH2 and MSH6.

Itkonen HM, Kantelinen J, Vaara M, Parkkinen S, Schlott B, Grosse F, Nyström M, Syväoja JE, Pospiech H.

FEBS Lett. 2016 Dec;590(23):4233-4241. doi: 10.1002/1873-3468.12475. Epub 2016 Nov 16.

13.

Using Chemical Probes to Assess the Feasibility of Targeting SecA for Developing Antimicrobial Agents against Gram-Negative Bacteria.

Jin J, Hsieh YH, Cui J, Damera K, Dai C, Chaudhary AS, Zhang H, Yang H, Cao N, Jiang C, Vaara M, Wang B, Tai PC.

ChemMedChem. 2016 Nov 21;11(22):2511-2521. doi: 10.1002/cmdc.201600421. Epub 2016 Oct 18.

14.

Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis.

Lahdensuo K, Rannikko A, Anttila VJ, Erickson A, Pätäri-Sampo A, Rautio M, Santti H, Tarkka E, Vaara M, Huotari K.

Prostate Cancer Prostatic Dis. 2016 Dec;19(4):417-422. doi: 10.1038/pcan.2016.36. Epub 2016 Aug 16.

PMID:
27526964
15.

A New Agility Test for Adults: Its Test-Retest Reliability and Minimal Detectable Change in Untrained Women and Men Aged 28-55.

Manderoos SA, Vaara ME, Mäki PJ, Mälkiä EA, Aunola SK, Karppi SL.

J Strength Cond Res. 2016 Aug;30(8):2226-34. doi: 10.1519/JSC.0000000000001318.

PMID:
26705068
16.

Evaluation of Antimicrobial Therapy of Blood Culture Positive Healthcare-Associated Infections in Children.

Laine N, Vaara M, Anttila VJ, Hoppu K, Laaksonen R, Airaksinen M, Saxen H.

PLoS One. 2015 Nov 5;10(11):e0141555. doi: 10.1371/journal.pone.0141555. eCollection 2015.

17.

Loratadine analogues as MAGL inhibitors.

Patel JZ, Ahenkorah S, Vaara M, Staszewski M, Adams Y, Laitinen T, Navia-Paldanius D, Parkkari T, Savinainen JR, Walczyński K, Laitinen JT, Nevalainen TJ.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42. doi: 10.1016/j.bmcl.2015.02.037. Epub 2015 Feb 24.

PMID:
25752982
18.

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors.

Patel JZ, Nevalainen TJ, Savinainen JR, Adams Y, Laitinen T, Runyon RS, Vaara M, Ahenkorah S, Kaczor AA, Navia-Paldanius D, Gynther M, Aaltonen N, Joharapurkar AA, Jain MR, Haka AS, Maxfield FR, Laitinen JT, Parkkari T.

ChemMedChem. 2015 Feb;10(2):253-65. doi: 10.1002/cmdc.201402453. Epub 2014 Dec 11.

19.

Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12).

Parkkari T, Haavikko R, Laitinen T, Navia-Paldanius D, Rytilahti R, Vaara M, Lehtonen M, Alakurtti S, Yli-Kauhaluoma J, Nevalainen T, Savinainen JR, Laitinen JT.

PLoS One. 2014 May 30;9(5):e98286. doi: 10.1371/journal.pone.0098286. eCollection 2014.

20.

Efficacy of a novel PCR- and microarray-based method in diagnosis of a prosthetic joint infection.

Metso L, Mäki M, Tissari P, Remes V, Piiparinen P, Kirveskari J, Tarkka E, Anttila VJ, Vaara M, Huotari K.

Acta Orthop. 2014 Apr;85(2):165-70. doi: 10.3109/17453674.2014.889978. Epub 2014 Feb 25.

21.

Rapid molecular characterization of Acinetobacter baumannii clones with rep-PCR and evaluation of carbapenemase genes by new multiplex PCR in Hospital District of Helsinki and Uusimaa.

Pasanen T, Koskela S, Mero S, Tarkka E, Tissari P, Vaara M, Kirveskari J.

PLoS One. 2014 Jan 21;9(1):e85854. doi: 10.1371/journal.pone.0085854. eCollection 2014.

22.

An outbreak of CTX-M-15 -producing Escherichia coli, Enterobacter cloacae, and Klebsiella in a children's hospital in Finland.

Pasanen T, Jalava J, Horsma J, Salo E, Pakarinen M, Tarkka E, Vaara M, Tissari P.

Scand J Infect Dis. 2014 Mar;46(3):225-30. doi: 10.3109/00365548.2013.857045. Epub 2013 Dec 5.

PMID:
24303912
23.

Applicability of DiversiLab repetitive sequence-based PCR method in epidemiological typing of enterohemorrhagic Escherichia coli (EHEC).

Lukinmaa-Åberg S, Horsma J, Pasanen T, Mero S, Aulu L, Vaara M, Siitonen A, Antikainen J.

Foodborne Pathog Dis. 2013 Jul;10(7):632-8. doi: 10.1089/fpd.2012.1411. Epub 2013 May 21.

PMID:
23692078
24.

A quantitative polymerase chain reaction assay for rapid detection of 9 pathogens directly from stools of travelers with diarrhea.

Antikainen J, Kantele A, Pakkanen SH, Lääveri T, Riutta J, Vaara M, Kirveskari J.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1300-1307.e3. doi: 10.1016/j.cgh.2013.03.037. Epub 2013 Apr 29.

PMID:
23639597
25.

Clinical isolates of Pseudomonas aeruginosa from superficial skin infections have different physiological patterns.

Buivydas A, Pasanen T, Senčilo A, Daugelavičius R, Vaara M, Bamford DH.

FEMS Microbiol Lett. 2013 Jun;343(2):183-9. doi: 10.1111/1574-6968.12148. Epub 2013 Apr 22.

26.

Novel derivatives of polymyxins.

Vaara M.

J Antimicrob Chemother. 2013 Jun;68(6):1213-9. doi: 10.1093/jac/dkt039. Epub 2013 Feb 13. Review.

PMID:
23412346
27.

The novel polymyxin derivative NAB739 is remarkably less cytotoxic than polymyxin B and colistin to human kidney proximal tubular cells.

Vaara M, Vaara T.

Int J Antimicrob Agents. 2013 Mar;41(3):292-3. doi: 10.1016/j.ijantimicag.2012.10.005. Epub 2012 Nov 20. No abstract available.

PMID:
23182536
28.

Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.

Vaara M, Sader HS, Rhomberg PR, Jones RN, Vaara T.

J Antimicrob Chemother. 2013 Mar;68(3):636-9. doi: 10.1093/jac/dks438. Epub 2012 Nov 6.

PMID:
23134658
29.

Repolarization abnormalities in patients with subarachnoid and intracerebral hemorrhage: predisposing factors and association with outcome.

Junttila E, Vaara M, Koskenkari J, Ohtonen P, Karttunen A, Raatikainen P, Ala-Kokko T.

Anesth Analg. 2013 Jan;116(1):190-7. doi: 10.1213/ANE.0b013e318270034a. Epub 2012 Oct 31.

PMID:
23115256
30.

Efficient long DNA gap-filling in a mammalian cell-free system: a potential new in vitro DNA replication assay.

Nakao S, Zhang S, Vaara M, Syväoja JE, Lee MY, Tsurimoto T, Karran P, Oda S.

Biochimie. 2013 Feb;95(2):320-8. doi: 10.1016/j.biochi.2012.09.031. Epub 2012 Oct 10.

PMID:
23063694
31.

Accurate and rapid identification of Candida spp. frequently associated with fungemia by using PCR and the microarray-based Prove-it Sepsis assay.

Aittakorpi A, Kuusela P, Koukila-Kähkölä P, Vaara M, Petrou M, Gant V, Mäki M.

J Clin Microbiol. 2012 Nov;50(11):3635-40. doi: 10.1128/JCM.01461-12. Epub 2012 Sep 5.

32.

Segregation of replicative DNA polymerases during S phase: DNA polymerase ε, but not DNA polymerases α/δ, are associated with lamins throughout S phase in human cells.

Vaara M, Itkonen H, Hillukkala T, Liu Z, Nasheuer HP, Schaarschmidt D, Pospiech H, Syväoja JE.

J Biol Chem. 2012 Sep 28;287(40):33327-38. Epub 2012 Aug 10.

33.

Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008-11).

Österblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, Jalava J.

J Antimicrob Chemother. 2012 Dec;67(12):2860-4. doi: 10.1093/jac/dks299. Epub 2012 Jul 31.

PMID:
22855858
34.

Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells.

Mingeot-Leclercq MP, Tulkens PM, Denamur S, Vaara T, Vaara M.

Peptides. 2012 Jun;35(2):248-52. doi: 10.1016/j.peptides.2012.03.033. Epub 2012 Apr 6.

PMID:
22504013
35.

Clonality behind the increase of multidrug-resistance among non-invasive pneumococci in Southern Finland.

Siira L, Jalava J, Tissari P, Vaara M, Kaijalainen T, Virolainen A.

Eur J Clin Microbiol Infect Dis. 2012 May;31(5):867-71. doi: 10.1007/s10096-011-1386-8. Epub 2011 Aug 26.

PMID:
21870053
36.

Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.

Seneviratne CJ, Wong SS, Yuen KY, Meurman JH, Pärnänen P, Vaara M, Samaranayake LP.

Mycopathologia. 2011 Nov;172(5):389-95. doi: 10.1007/s11046-011-9444-4. Epub 2011 Jul 9.

PMID:
21744043
37.

Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.

Nilsson LE, Frimodt-Møller N, Vaara M, Simonsen GS; Tigecycline Study Group.

Scand J Infect Dis. 2011 Sep;43(9):707-13. doi: 10.3109/00365548.2011.581305. Epub 2011 May 30.

PMID:
21619494
38.

Isolation and characterization of Streptococcus mitis from blood of child with osteomyelitis.

Nomura R, Nakano K, Mäkelä K, Vaara M, Salo E, Alaluusua S, Ooshima T.

Int J Paediatr Dent. 2011 May;21(3):192-9. doi: 10.1111/j.1365-263X.2010.01110.x. Epub 2010 Dec 29.

PMID:
21199004
39.

Shiga toxin-producing Escherichia coli O100:H⁻: stx2e in drinking water contaminated by waste water in Finland.

Lienemann T, Pitkänen T, Antikainen J, Mölsä E, Miettinen I, Haukka K, Vaara M, Siitonen A.

Curr Microbiol. 2011 Apr;62(4):1239-44. doi: 10.1007/s00284-010-9832-x. Epub 2010 Dec 25.

PMID:
21188590
40.

Polymyxins and their novel derivatives.

Vaara M.

Curr Opin Microbiol. 2010 Oct;13(5):574-81. doi: 10.1016/j.mib.2010.09.002. Epub 2010 Sep 24. Review.

PMID:
20869908
41.

Structure-activity studies on novel polymyxin derivatives that carry only three positive charges.

Vaara M, Vaara T.

Peptides. 2010 Dec;31(12):2318-21. doi: 10.1016/j.peptides.2010.09.010. Epub 2010 Sep 22.

PMID:
20868714
42.

Pneumococcal serotype distribution in invasive paediatric disease in Southern Finland before the introduction of vaccine.

Laitinen S, Vaara M, Salo E.

Scand J Infect Dis. 2010 Dec;42(11-12):924-30. doi: 10.3109/00365548.2010.510532. Epub 2010 Aug 25.

PMID:
20735331
43.

Emergence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae during the years 2000 and 2004 in Helsinki, Finland.

Forssten SD, Kolho E, Lauhio A, Lehtola L, Mero S, Oksaharju A, Jalava J, Tarkka E, Vaara M, Vuopio-Varkila J.

Clin Microbiol Infect. 2010 Aug;16(8):1158-61. doi: 10.1111/j.1469-0691.2010.03068.x.

44.

A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.

Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T.

Antimicrob Agents Chemother. 2010 Aug;54(8):3341-6. doi: 10.1128/AAC.01439-09. Epub 2010 May 17.

45.

Comparison of repetitive extragenic palindromic sequence-based PCR with PCR ribotyping and pulsed-field gel electrophoresis in studying the clonality of Clostridium difficile.

Pasanen T, Kotila SM, Horsma J, Virolainen A, Jalava J, Ibrahem S, Antikainen J, Mero S, Tarkka E, Vaara M, Tissari P.

Clin Microbiol Infect. 2011 Feb;17(2):166-75. doi: 10.1111/j.1469-0691.2010.03221.x.

46.

Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice.

Vingsbo Lundberg C, Vaara T, Frimodt-Møller N, Vaara M.

J Antimicrob Chemother. 2010 May;65(5):981-5. doi: 10.1093/jac/dkq072. Epub 2010 Mar 16.

PMID:
20233777
47.

Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin.

Vaara M, Siikanen O, Apajalahti J, Frimodt-Møller N, Vaara T.

J Antimicrob Chemother. 2010 May;65(5):942-5. doi: 10.1093/jac/dkq040. Epub 2010 Feb 18.

PMID:
20167589
48.

A selective broth enrichment combined with real-time nuc-mecA-PCR in the exclusion of MRSA.

Pasanen T, Korkeila M, Mero S, Tarkka E, Piiparinen H, Vuopio-Varkila J, Vaara M, Tissari P.

APMIS. 2010 Jan;118(1):74-80. doi: 10.1111/j.1600-0463.2009.02562.x.

PMID:
20041874
49.

Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study.

Tissari P, Zumla A, Tarkka E, Mero S, Savolainen L, Vaara M, Aittakorpi A, Laakso S, Lindfors M, Piiparinen H, Mäki M, Carder C, Huggett J, Gant V.

Lancet. 2010 Jan 16;375(9710):224-30. doi: 10.1016/S0140-6736(09)61569-5. Epub 2009 Dec 10.

PMID:
20004964
50.

[Evolution of pathogenic micro-organisms as a challenge for medicine].

Vaara M.

Duodecim. 2009;125(18):2001-6. Finnish.

PMID:
19860083

Supplemental Content

Support Center